W2J logo

Carisma Therapeutics DB:W2J Stock Report

Last Price

€0.39

Market Cap

€16.0m

7D

-9.8%

1Y

-85.8%

Updated

25 Dec, 2024

Data

Company Financials +

Carisma Therapeutics, Inc.

DB:W2J Stock Report

Market Cap: €16.0m

W2J Stock Overview

A clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. More details

W2J fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Carisma Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Carisma Therapeutics
Historical stock prices
Current Share PriceUS$0.39
52 Week HighUS$2.82
52 Week LowUS$0.37
Beta0
1 Month Change-49.36%
3 Month Change-54.35%
1 Year Change-85.83%
3 Year Changen/a
5 Year Changen/a
Change since IPO-34.80%

Recent News & Updates

Recent updates

Shareholder Returns

W2JDE BiotechsDE Market
7D-9.8%-0.8%-1.6%
1Y-85.8%-13.0%6.8%

Return vs Industry: W2J underperformed the German Biotechs industry which returned -13.2% over the past year.

Return vs Market: W2J underperformed the German Market which returned 6.8% over the past year.

Price Volatility

Is W2J's price volatile compared to industry and market?
W2J volatility
W2J Average Weekly Movement13.6%
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: W2J's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: W2J's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2016107Steve Kellywww.carismatx.com

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases.

Carisma Therapeutics, Inc. Fundamentals Summary

How do Carisma Therapeutics's earnings and revenue compare to its market cap?
W2J fundamental statistics
Market cap€16.02m
Earnings (TTM)-€61.37m
Revenue (TTM)€19.50m

0.8x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
W2J income statement (TTM)
RevenueUS$20.27m
Cost of RevenueUS$63.51m
Gross Profit-US$43.24m
Other ExpensesUS$20.56m
Earnings-US$63.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.53
Gross Margin-213.35%
Net Profit Margin-314.78%
Debt/Equity Ratio0%

How did W2J perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 13:42
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Carisma Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Justin ZelinBTIG
Naureen QuibriaCapital One Securities, Inc.